Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 6;6(3):e154–e166. doi: 10.1016/S2352-3026(18)30220-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Box-plots showing percentage of protocol dose delivered in NCRI-XI and EORTC QLQ-C30 subscale scores in MRC-IX across the MRP groups

(A) Percentage of protocol dose delivered in NCRI Myeloma XI (NCRI-XI; n=1852) for induction regimen. (B) Percentage of protocol dose delivered in NCRI-XI (n=157) for consolidation regimen. (C) EORTC QLQ-C30 subscale scores in MRC Myeloma IX (MRC-IX; n=466) for global health status/quality of life. Higher values indicate improved response. (D) EORTC QLQ-C30 subscale scores in MRC-IX for side-effects of treatment measured at baseline. Higher values indicate worse response. All data are median (IQR). Symbols (round circles, +, and ×) indicate outliers. CRDa=attenuated cyclophosphamide, lenalidomide, and dexamethasone. CTDa= attenuated cyclophosphamide, thalidomide, and dexamethasone. CVD=cyclophosphamide, bortezomib, and dexamethasone. MRP=UK Myeloma Research Alliance Risk Profile.